	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	83.57	100.14	123.01	151.55	202.20	245.52	305.58	350.77	378.84	487.70	779.16	690.62	806.67	819.81	944.01	981.10
Cost of Operating Revenue	51.39	59.23	68.59	85.05	105.77	138.98	165.77	208.55	212.07	288.50	458.73	386.55	444.40	436.18	521.49	466.23
Gross Profit	32.17	40.91	54.42	66.50	96.43	106.54	139.81	142.21	166.77	199.20	320.42	304.07	362.27	383.63	422.51	514.87
Gross Margin	38.5	40.9	44.2	43.9	47.7	43.4	45.8	40.5	44.0	40.8	41.1	44.0	44.9	46.8	44.8	52.5
Total Operating Expenses	78.33	91.16	113.45	140.89	186.30	226.25	271.19	309.43	340.30	420.05	650.57	575.29	675.51	702.47	823.50	847.28
Operating Profit	5.24	8.98	9.56	10.66	15.90	19.27	34.39	41.34	38.54	67.65	128.58	115.33	131.15	117.33	120.51	133.82
Operating Margin	6.3	9.0	7.8	7.0	7.9	7.8	11.3	11.8	10.2	13.9	16.5	16.7	16.3	14.3	12.8	13.6
Financing Income/(Expense) - Net	-2.51	-3.88	-3.62	-4.71	-6.20	-5.10	-7.86	-8.83	-12.81	-10.75	-2.27	-9.77	-13.45	-25.24	-34.50	-36.70
Profit before Taxes	2.97	5.26	6.27	6.53	10.36	14.37	29.95	35.35	30.13	57.71	126.84	106.72	115.67	94.14	86.55	99.31
Income Taxes	1.44	1.93	2.01	2.37	3.03	5.35	13.48	13.41	7.44	13.48	31.00	27.02	29.54	24.49	22.34	25.86
Profit after Tax	1.53	3.33	4.26	4.16	7.32	9.02	16.48	21.94	22.69	44.23	95.84	79.70	86.14	69.65	64.21	73.46
PAT Margin	1.8	3.3	3.5	2.7	3.6	3.7	5.4	6.3	6.0	9.1	12.3	11.5	10.7	8.5	6.8	7.5
EPS - Basic - ex Extraordinary Items	0.20	0.43	0.55	0.54	0.95	1.17	2.12	2.82	2.34	4.56	9.89	8.22	8.74	6.95	6.40	7.32
EPS - Diluted - ex Extraordinary Items	0.20	0.43	0.55	0.54	0.95	1.17	2.12	2.82	2.34	4.56	9.89	8.22	8.74	6.95	6.40	7.32
EBIT	5.24	8.98	9.56	10.66	15.90	19.27	34.39	41.34	38.54	67.65	128.58	115.33	131.15	117.33	120.51	133.82
EBITDA	7.12	11.16	12.03	14.52	19.68	22.95	38.79	45.99	52.40	83.96	145.71	137.61	148.17	138.39	151.34	164.64
EBITDA Margin	8.5	11.1	9.8	9.6	9.7	9.3	12.7	13.1	13.8	17.2	18.7	19.9	18.4	16.9	16.0	16.8

Balance Sheet

Abridged

Understanding Balance Sheet

Gufic Biosciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	50	52	69	91	119	143	198	233	273	261	321	464	600	625	802
Long-Term Investments	0	0	0	0	2	2	0	0	0	0	0	1	2	2	2
Property Plant & Equipment - Net	18	30	30	25	22	22	24	34	113	113	155	328	460	521	507
Total Non-Current Assets	24	37	42	36	33	35	40	47	134	131	201	397	492	545	540
Total Assets	74	90	111	127	152	178	238	280	408	392	521	861	1,093	1,169	1,342
Total Current Liabilities	46	44	60	84	110	128	169	186	240	164	186	288	372	388	518
Long Term Debt	4	18	15	12	7	7	8	11	26	38	48	207	166	150	119
Total Non-Current Liabilities	9	24	25	17	13	13	15	18	38	55	66	225	188	181	160
Total Liabilities	55	67	85	100	123	141	184	204	278	219	252	513	560	568	677
Total Shareholders' Equity	20	22	26	27	29	37	54	75	129	173	269	348	533	601	665
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Total Equity	20	22	26	27	29	37	54	75	129	173	269	348	533	601	665
Total Liabilities & Equity	74	90	111	127	152	178	238	280	408	392	521	861	1,093	1,169	1,342

Cash Flow

Abridged

Understanding Cash Flow Statement

Gufic Biosciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	4.41	6.26	7.25	8.42	11.89	8.08	4.10	15.95	24.04	52.75	81.72	74.73	79.56	62.10	83.48
Working Capital - Increase/(Decrease)	-1.87	-4.74	-0.19	-1.62	-21.31	-18.36	-16.93	-20.11	9.92	23.45	20.28	-108.24	-100.69	31.94	-72.49
Net CF from Operating Activities	2.55	1.52	7.06	6.80	-9.43	-10.28	-12.83	-4.16	33.96	76.20	102.00	-33.51	-21.13	94.04	10.99
Capital Expenditures - Net	3.34	13.35	2.89	2.50	0.77	4.15	8.24	13.08	39.83	14.21	87.38	187.57	108.13	70.76	31.18
Net CF from Investing Activities	-3.34	-13.35	-2.89	-2.50	-0.77	-4.81	-8.97	-13.37	-43.12	-9.06	-95.16	-191.71	-103.39	-71.71	-31.97
Dividends Paid - Cash - Total	0.39	0.37	0.39	0.39	0.39	0.39	0.39	0.39	0.49	0.36	0.92	1.04	0.97	1.00	1.00
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-	-	-	99.99	-	0.10
Debt - LT & ST - Issuance/(Retirement) - Total	1.19	12.52	-2.52	-0.25	10.54	14.09	22.96	18.07	10.02	-64.84	-0.29	243.47	-1.40	-6.74	68.56
Net Cash Flow from Financing Activities	0.81	12.15	-2.91	-0.63	10.15	13.68	22.55	17.46	9.53	-65.20	-1.43	242.21	97.06	-7.75	67.44
Free Cash Flow to Equity	0.40	0.69	1.65	4.05	0.34	-0.34	1.89	0.83	4.14	-2.85	14.32	22.40	-130.66	16.54	48.37
Free Operating CF net dividend	-1.18	-12.23	2.73	3.90	-10.79	-14.82	-21.46	-17.63	-6.38	61.63	13.63	-222.15	-134.80	17.51	-21.19
Free Operating CF	-0.79	-11.86	3.12	4.29	-10.40	-14.43	-21.07	-17.24	-5.89	61.99	14.55	-221.11	-133.83	18.52	-20.19

Business Segment Analysis

FY End:

Mar 26

Gufic Biosciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 31.18 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 944.01 Cr

Assets

Pharmaceuticals (100.0%)₹ 1,342.37 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 120.51 Cr

Regional Segment Analysis

FY End:

Mar 26

Gufic Biosciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (77.0%)₹ 727.02 CrEurope (9.5%)₹ 89.42 CrAsia (6.9%)₹ 65.18 CrNorthern America (3.4%)₹ 32.07 CrAfrica (2.8%)₹ 26.89 CrSouth America (0.3%)₹ 2.96 CrAustralia (0.0%)₹ 0.47 Cr

Historical Segment Analysis

Track how Gufic Biosciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceuticals	-	-	-	-	40	14	89	188	113	76	31
Agro Products	0	0	-	-	-	-	-	-	-	-	-
Bulk Drugs	0	0	0	1	-	-	-	-	-	-	-
Chemical	0	-	-	-	-	-	-	-	-	-	-
Consumer	0	0	0	2	-	-	-	-	-	-	-
Formulation	1	4	2	8	-	-	-	-	-	-	-
Unallocated	0	0	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Gufic Biosciences Ltd.?

The latest trailing twelve month revenue of Gufic Biosciences Ltd. is ₹ 981.10 Cr, reflecting a 1-year growth of 16.70% and a 3-year CAGR of 10.85%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Gufic Biosciences Ltd.?

The latest trailing twelve month net profit (PAT) of Gufic Biosciences Ltd. is ₹ 73.46 Cr, with a 3-year earnings CAGR of -3.66%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Gufic Biosciences Ltd.?

The trailing twelve month EBITDA of Gufic Biosciences Ltd. is approximately ₹ 133.82 Cr (based on an operating margin of 13.64%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Gufic Biosciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Gufic Biosciences Ltd. is 7.32. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Gufic Biosciences Ltd.?

The debt-to-equity ratio of Gufic Biosciences Ltd. stands at 0.61. The interest coverage ratio is 3.65x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Gufic Biosciences Ltd.?

The estimated book value per share of Gufic Biosciences Ltd. is 66.31 (derived from a P/B ratio of 5.91 and market price of ₹ 391.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Gufic Biosciences Ltd.?

The trailing twelve month operating cash flow of Gufic Biosciences Ltd. is ₹ 13.17 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Gufic Biosciences Ltd. report consolidated or standalone financials?

Gufic Biosciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.